Science was not a challenge for India, but its translation was a bottleneck for our country, said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, on Wednesday as she noted the 21st century belongs to Biology and Biotechnology, led by AI.
Unveiled by Biocon Chairperson Kiran Mazumdar-Shaw, the programme is part of the Station Access and Mobility Program (STAMP), led by WRI India and Toyota Mobility Foundation at Electronics City, Bengaluru.
Indian pharmaceuticals giant Biocon registered Rs 3,516 crore revenues for Quarter 1 of FY 2024. An official statement issued by…
Biocon Biologics, a subsidiary of pharmaceutical giant Biocon Ltd, has made several key leadership appointments which will play an important…
"We reported strong consolidated revenue growth of 21 percent for Q4FY22 at Rs 2,476 crore driven by 48 percent growth in Biosimilars, 26 percent in Generics, and 15 percent in Research Services businesses."
Company’s expense rose by 14.52 per cent to Rs 1,642.6 crore during the quarter under review. In the year-ago period it was at Rs 1,434.3 crore.
"I have added to the Covid count by testing positive. Mild symptoms and I hope it stays that way," tweeted the 67-year-old city-based biotech queen Shaw.
